Lipid-Like Nanoparticles for Small Interfering RNA Delivery to Endothelial Cells
Article first published online: 25 AUG 2009
Copyright © 2009 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim
Advanced Functional Materials
Volume 19, Issue 19, pages 3112–3118, October 9, 2009
How to Cite
Cho, S.-W., Goldberg, M., Son, S. M., Xu, Q., Yang, F., Mei, Y., Bogatyrev, S., Langer, R. and Anderson, D. G. (2009), Lipid-Like Nanoparticles for Small Interfering RNA Delivery to Endothelial Cells. Adv. Funct. Mater., 19: 3112–3118. doi: 10.1002/adfm.200900519
- Issue published online: 5 OCT 2009
- Article first published online: 25 AUG 2009
- Manuscript Received: 19 MAR 2009
- National Institutes of Health. Grant Number: EB000244
- Alnylam Pharmaceuticals, Inc.
- Endothelial Cells;
- siRNA delivery
Here, nanoparticles composed of lipid-like materials (lipidoids) to facilitate non-viral delivery of small interfering RNA (siRNA) to endothelial cells (ECs) are developed. Nanoparticles composed of siRNA and lipidoids with small size (∼200 nm) and positive charge (∼34 mV) are formed by self-assembly of lipidoids and siRNA. Ten lipidoids are synthesized and screened for their ability to facilitate the delivery of siRNA into ECs. Particles composed of leading lipidoids show significantly better delivery to ECs than a leading commercially available transfection reagent, Lipofectamine 2000. As a model of potential therapeutic application, nanoparticles composed of the top performing lipidoid, NA114, are studied for their ability to deliver siRNA targeting anti-angiogenic factor (SHP-1) to human ECs. Silencing of SHP-1 expression significantly enhances EC proliferation and decreases EC apoptosis under a simulated ischemic condition.